Clinical efficacy and safety of istradefylline in the treatment of advanced Parkinson's disease: a retrospective study
Not Applicable
Completed
- Conditions
- Parkinson's disease
- Registration Number
- JPRN-UMIN000020562
- Lead Sponsor
- Himeji Central Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
?Patients who received istradefylline in the period from May 2013 to May 2015
?Parkinson's disease patients having wearing-off phenomenon under treatment with medications containing levodopa
?Outpatient
Exclusion Criteria
?Patients who have moderate or severer hepatic disorder or are receiving strong CYP3A4 inhibitors.
?Women who are lactating or pregnant or are suspected of being pregnant.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical global impression<br>Improvement for each motor symptom
- Secondary Outcome Measures
Name Time Method Safety
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of istradefylline improve motor symptoms in advanced Parkinson's disease patients?
How does istradefylline compare to standard dopamine agonists in managing Parkinson's disease motor fluctuations?
Are there specific biomarkers associated with istradefylline response in Parkinson's disease observational studies?
What adverse events are commonly reported with istradefylline in Parkinson's disease treatment regimens?
What combination therapies with istradefylline show promise in advanced Parkinson's disease management?